RedHill Biopharma Ltd. (RDHL) Announces Positive European Regulatory Meetings Regarding Its European Phase III Plan for RHB-104 (Crohn's)
8/20/2013 9:13:20 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
TEL-AVIV, Israel, Aug. 20, 2013 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) (the "Company" or "RedHill"), an emerging Israeli biopharmaceutical company focused primarily on the development and acquisition of late clinical-stage, proprietary formulations and combinations of existing drugs, reported that it had recently concluded Scientific Advice Meetings with the UK Medicines and Healthcare Products Regulatory Agency (MHRA) and the Swedish Medical Products Agency (MPA) regarding the regulatory path towards a Phase III clinical study in Europe with RHB-104. RHB-104 is a proprietary and potentially groundbreaking combination antibiotic therapy with potent anti-bacterial and anti-inflammatory properties, in oral pill form, targeting Crohn's disease, multiple sclerosis, rheumatoid arthritis and other unmet medical needs.
Help employers find you! Check out all the jobs and post your resume.